Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...
The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
2025 As a senior in high school who is anxiously awaiting the beginning of her BFA musical theater journey, I'm trying to savor every last moment of high school.
A new musical based on the iconic 1930s cartoon character.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback